Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

ClinicalTrials.gov ID: NCT05756569

Public ClinicalTrials.gov record NCT05756569. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving enfortumab vedotin and pembrolizumab may kill more tumor cells in patients with locally advanced or metastatic bladder cancer of variant histology.

Study identification

NCT ID: NCT05756569
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Emory University; Other
Enrollment: 25 participants

Conditions and interventions

Conditions

Interventions

Procedure · Drug · Biological + 1 more

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 25, 2023
Primary completion: Dec 15, 2026
Completion: Dec 15, 2027
Last update posted: Jul 28, 2026

2023 – 2027

United States locations

U.S. sites: 4
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Grady Health System	Atlanta	Georgia	30303	Recruiting
Emory University Hospital Midtown	Atlanta	Georgia	30308	Recruiting
Emory University Hospital/Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
Emory Saint Joseph's Hospital	Atlanta	Georgia	30342	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05756569, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 28, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05756569 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →